3.2. Remdesivir therapy and other drugs in RDV-treated patients
Almost three-quarters of patients from the RDV-treated group received the drug for 5 days in accordance with the summary of product characteristics. RDV was administered for over 5 days in six patients who were non-immunocompetent or had numerous risk factors for a severe course of the disease. The majority of patients treated with RDV in both waves of the pandemic received the drug within the first 5 days of symptom onset, with the drug being switched on significantly faster in the Omicron wave, 3.5±2.2 days compared to the Delta dominant period, 5.1±3.0 days, p<0.001 (Table 3).
Table 3. Remdesivir therapy and other drugs used in RDV-treated patients during Delta and Omicron waves.